sorafenib has been researched along with Venous Thrombosis in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (3.23) | 29.6817 |
| 2010's | 42 (67.74) | 24.3611 |
| 2020's | 18 (29.03) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, BQ; Gao, YJ; Tao, ZW; Zhou, T | 1 |
| Chung, JW | 1 |
| Fujinaga, Y; Hokuto, D; Kawaratani, H; Kitagawa, K; Narita, H; Nishimura, N; Ozutsumi, T; Shibamoto, A; Sho, M; Takeda, S; Tsuji, Y; Yoshiji, H | 1 |
| Fukumoto, T; Kido, M; Komatsu, S; Ku, Y; Kudo, M; Kuramitsu, K; Toyama, H; Tsugawa, D; Ueshima, K; Yanagimoto, H | 1 |
| Ang, C; Balcar, L; Bettinger, D; Cammarota, A; Cheon, J; Chon, HJ; Cortellini, A; D'Alessio, A; Fulgenzi, CAM; Gaillard, VE; Galle, PR; Huang, YH; Kudo, M; Marron, TU; Masi, G; Napolitano, A; Naqash, AR; Nishida, N; Personeni, N; Phen, S; Pinato, DJ; Pinter, M; Pressiani, T; Rimassa, L; Saeed, A; Salani, F; Scheiner, B; Schönlein, M; Schulze, K; Sharma, R; Singal, AG; Vivaldi, C; Vogel, A; von Felden, J; Wege, H; Wietharn, B; Wu, L | 1 |
| Deng, M; Guo, R; Li, S; Wei, W | 1 |
| Ahn, YE; Jung, YK; Kim, TH; Yim, HJ | 1 |
| Cao, GS; Chen, SQ; Gao, K; Guo, JH; Ji, JS; Lau, WY; Li, HL; Li, R; Li, YL; Lu, D; Lu, J; Lu, LG; Lv, WF; Min, J; Ren, WX; Shao, HB; Sun, JH; Teng, GJ; Wang, WD; Wang, WJ; Wu, FZ; Yang, P; Yin, GW; Zhang, FJ; Zhao, Y; Zhu, GY; Zhu, HD | 1 |
| Chen, R; Li, L; Ma, H; Ren, Z; Tang, B; Xie, X; Yin, X; Yuan, J; Zhang, L | 1 |
| Chen, XP; Dong, HH; Dong, KS; Zhang, EL; Zhang, LW; Zhang, ZY | 1 |
| Liu, M; Mou, T; Shen, A; Shi, J; Wang, Y; Wu, Z | 1 |
| Bertacco, A; Cillo, U; Mescoli, C; Vitale, A | 1 |
| Ho, CH; Huang, CI; Li, LC; Lin, CH; Que, J; Wu, HC | 1 |
| Fujishiro, M; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Ito, T; Kuzuya, T | 1 |
| Chen, YJ; Hsieh, CH; Huang, HL; Huang, YC; Tai, HC; Tsai, TH; Wang, LY | 1 |
| Aydin, C; Yilmaz, S | 1 |
| Li, J; Liu, Y; Wang, Z; Wu, H; Xie, K; Zeng, Y | 1 |
| Abdelaziz, AO; Abdelhady, RSM; Abdelmaksoud, AHK; Elbaz, TM; Hamza, I; Lithy, R; Nabeel, MM; Shousha, HI | 1 |
| Berchialla, P; Burlone, ME; Carucci, P; Gaia, S; Gesualdo, M; Martelletti, C; Mattalia, A; Okolicsanyi, S; Pirisi, M; Ricotti, A; Rolle, E; Tabone, M | 1 |
| Li, X; Shi, D; Wang, F; Wang, J; Zhang, J | 1 |
| Bie, P; Chen, X; Dou, K; Liu, F; Liu, L; Yang, J; Yang, X; Ye, SL; Yip, CS; Zhang, S; Zhou, J | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kee, KM; Kuo, YH; Lu, SN; Rau, KM; Wang, JH; Wu, IP | 1 |
| Byun, KS; Jung, YK; Kang, SH; Kim, BH; Kim, JH; Kim, TS; Lee, YS; Seo, YS; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ | 1 |
| Chai, W; Jiang, T; Tian, G | 1 |
| Zhang, H | 1 |
| Liu, LX; Liu, QX; Luo, JJ; Ma, JQ; Wang, JH; Yan, ZP; Zhang, W; Zhang, ZH | 1 |
| Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ | 1 |
| Lu, XJ; Wang, JC; Xia, AL; Xu, Y | 1 |
| Choi, SH; Kim, JH; Kim, PH; Park, SH | 1 |
| Ebert, MP; Schlitt, HJ; Sollors, J; Steinebrunner, N; Stroszczynski, C; Teufel, A; Weiss, KH; Zhan, T | 1 |
| Axelsson, R; Brismar, TB; Haji, M; Karalli, A; Seth, E; Stål, P; Teiler, J; Wahlin, S | 1 |
| Cheng, SQ; Davidson, JC; Lau, WY; Lu, J; Madoff, DC; Qi, X; Teng, GJ; Zhang, XP; Zhong, BY | 1 |
| Di Fiore, A; Di Fiore, F; Drieux, F; François, A; Kermiche-Rahali, S; Scotté, M | 1 |
| Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, JH; Kim, KH; Kim, SG; Kim, YS; Lee, SH; Shim, KY | 1 |
| Chen, SW; Chiou, JF; Kuo, CC; Kuo, YC; Liang, JA; Lin, LC | 1 |
| Ahn, H; Hong, JH; Jeong, IG; Kim, CS; Kwon, T; Lee, JL; Song, C; You, D | 1 |
| Cai, M; Chen, J; Huang, W; Lai, L; Meng, X; Shan, H; Zhou, B; Zhu, K | 1 |
| Hidaka, H; Koizumi, W; Kokubu, S; Minamino, T; Nakazawa, T; Okuwaki, Y; Shibuya, A; Takada, J; Tanaka, Y; Watanabe, M | 1 |
| Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ | 1 |
| Li, W; Li, XS; Pan, T; Wang, JP; Wu, PH; Xie, QK; Zhao, M | 1 |
| Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S | 1 |
| Chen, J; Chen, S; Wu, B; Xi, W; Yu, H | 1 |
| Chung, YH; Jung, J; Kang, YK; Kim, GA; Kim, JH; Kim, KM; Lee, D; Lee, HC; Lee, YS; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Yoon, SM | 1 |
| Kim, YH; Lee, EW; Quirk, M; Saab, S | 1 |
| Heo, J; Woo, HY | 1 |
| Fujimoto, Y; Hatano, E; Kaido, T; Kitajima, T; Minamiguchi, S; Mitsunori, Y; Mizumoto, M; Okajima, H; Taura, K; Uemoto, S | 1 |
| Adhoute, X; Blanc, JF; Boucher, E; Boudjema, K; Campillo-Gimenez, B; Clément, B; Crouzet, L; Edeline, J; Garin, E; Guillygomarc'h, A; Lenoir, L; Pracht, M; Rohou, T; Rolland, Y | 1 |
| Gwon, DI; Han, K; Kim, JH; Ko, GY; Sung, KB | 1 |
| Deguchi, S; Kanazawa, A; Kawasaki, Y; Kioka, K; Kurihara, S; Murata, A; Nakai, T; Sakae, M; Shimizu, S; Tashima, T; Tsukamoto, T | 1 |
| Chen, MS; Cheng, SQ; Cong, WM; Guo, WX; Lau, WY; Mao, YL; Meng, Y; Shi, J; Sun, BC; Wang, K; Wu, MC; Yang, YF; Zhang, YJ | 1 |
| Chauhan, AK; Choi, SM; Choi, WY; Chung, WJ; Hwang, JS; Jang, BK; Kang, KJ; Kim, BS; Kim, YH; Kweon, YO; Lee, CH; Lee, JM; Lee, YJ; Park, SY; Tak, WY | 1 |
| Bai, T; Chen, J; Chen, JZ; Li, LQ; Lu, Z; Ma, L; Peng, YC; Qin, HG; Xiang, BD; Xie, ZB; Ye, HH; Ye, JZ | 1 |
| Bae, SH; Cho, YY; Chung, JW; Gwak, GY; Heo, J; Kim, do Y; Kim, HC; Kim, YH; Kim, YJ; Lee, M | 1 |
| Chapiro, J; Duran, R; Gebauer, B; Geschwind, JF; Gorodetski, B; Lee, H; Lenis, D; Lin, M; Nonyane, BA; Pawlik, TM; Pekurovsky, V; Schernthaner, R; Schlachter, T; Stuart, EA; Tamrazi, A | 1 |
| Amikura, K; Kageyama, Y; Kokudo, T; Miyazaki, Y; Sakamoto, H; Takahashi, A; Takano, M | 1 |
| Chung, CY; Wu, SS; Yen, HH | 1 |
| Bart, S; Billemont, B; Bitker, MO; Izzedine, H; Rixe, O; Sultan, V; Thibault, F | 1 |
| Audrain, O; Boucher, E; Leroux, C; Pracht, M; Raoul, JL; Vauléon, E; Zoheir, Y | 1 |
| Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Nakatake, R; Yanagimoto, Y | 1 |
| Belghiti, J; Chopin-Laly, X; Faivre, S; Irtan, S; Paradis, V; Ronot, M | 1 |
| Gotoh, M; Kashiwagi, Y; Nakano, Y; Takeda, H; Yoshino, Y | 1 |
| Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Matsushima, H; Nakatake, R; Sakaguchi, T | 1 |
12 review(s) available for sorafenib and Venous Thrombosis
| Article | Year |
|---|---|
Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Portal Vein; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis | 2022 |
Resection might be a meaningful choice for hepatocellular carcinoma with portal vein thrombosis: A systematic review and meta-analysis.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Conservative Treatment; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Portal Vein; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2019 |
Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Neoplasm Staging; Neoplastic Cells, Circulating; Portal Vein; Prognosis; Safety; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2020 |
Is Macroscopic Portal Vein Tumor Thrombosis of HCC Really an Exclusion for Liver Transplantation?
Topics: Carcinoma, Hepatocellular; Disease-Free Survival; Embolization, Therapeutic; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Portal Vein; Preoperative Care; Radiosurgery; Sorafenib; Venous Thrombosis | 2020 |
Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed; Venous Thrombosis | 2017 |
Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Portal Vein; Radiotherapy; Sorafenib; Treatment Outcome; Venous Thrombosis | 2019 |
Comparison of Radioembolization and Sorafenib for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis of Safety and Efficacy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diarrhea; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Severity of Illness Index; Sorafenib; Venous Thrombosis | 2019 |
Pharmacological treatment of hepatocellular carcinoma with cavoatrial tumor thrombus - case series and literature review.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fatal Outcome; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Sorafenib; Thrombosis; Vena Cava, Inferior; Venous Thrombosis | 2019 |
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Endovascular Procedures; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Liver Transplantation; Nivolumab; Patient Care Team; Phenylurea Compounds; Portal Vein; Pyridines; Quinolines; Radiotherapy, Adjuvant; Ramucirumab; Sorafenib; Stents; Venous Thrombosis | 2019 |
Management of hepatocellular carcinoma with portal vein thrombosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contraindications; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Portal Vein; Practice Guidelines as Topic; Protein Kinase Inhibitors; Radiopharmaceuticals; Sorafenib; Treatment Outcome; Venous Thrombosis | 2015 |
New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Sorafenib; Venous Thrombosis | 2015 |
Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review.
Topics: ADAM17 Protein; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Embolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Radiotherapy, Conformal; Sorafenib; Venous Thrombosis | 2016 |
7 trial(s) available for sorafenib and Venous Thrombosis
| Article | Year |
|---|---|
Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Portal Vein; Retrospective Studies; Sorafenib; Stents; Treatment Outcome; Venous Thrombosis | 2023 |
Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Hepatocellular; China; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Treatment Outcome; Venous Thrombosis | 2017 |
Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Portal Vein; Propensity Score; Retrospective Studies; Sorafenib; Stents; Survival Rate; Treatment Outcome; Venous Thrombosis | 2017 |
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters, Indwelling; Cisplatin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Portal Vein; Prospective Studies; Sorafenib; Survival Rate; Venous Thrombosis | 2018 |
Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Proportional Hazards Models; Sorafenib; Tomography, Spiral Computed; Venous Thrombosis | 2013 |
Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoradiotherapy; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fibrosis; Hand-Foot Syndrome; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiation Dosage; Sorafenib; Time Factors; Treatment Outcome; Venous Thrombosis | 2014 |
Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Female; Humans; Liver Function Tests; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Rate; Tomography, Spiral Computed; Treatment Outcome; Venous Thrombosis | 2014 |
43 other study(ies) available for sorafenib and Venous Thrombosis
| Article | Year |
|---|---|
Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in the Era of New Systemic Agents.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Portal Vein; Sorafenib; Venous Thrombosis | 2022 |
Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case report.
Topics: Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Interferons; Liver Neoplasms; Male; Portal Vein; Sorafenib; Thrombosis; Venous Thrombosis | 2022 |
Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: A bi-institutional propensity-matched cohort study.
Topics: Carcinoma, Hepatocellular; Cohort Studies; Hepatectomy; Humans; Liver Neoplasms; Portal Vein; Retrospective Studies; Sorafenib; Thrombosis; Treatment Outcome; Venous Thrombosis | 2023 |
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Topics: Albumins; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bilirubin; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Sorafenib; Venous Thrombosis | 2022 |
Comments on Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Portal Vein; Sorafenib; Treatment Outcome; Venous Thrombosis | 2023 |
Comments on Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Reply.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Portal Vein; Sorafenib; Treatment Outcome; Venous Thrombosis | 2023 |
Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Female; Hepatitis B virus; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Portal Vein; Sorafenib; Treatment Outcome; Venous Thrombosis | 2019 |
Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection.
Topics: Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Portal Vein; Sorafenib; Treatment Outcome; Venous Thrombosis | 2020 |
Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Portal Vein; Progression-Free Survival; Radiation Dosage; Radiosurgery; Retrospective Studies; Sorafenib; Taiwan; Venous Thrombosis | 2020 |
Sorafenib
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Portal Vein; Quinolines; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Venous Thrombosis | 2020 |
Robust combination of liver stereotactic body radiotherapy modulates pharmacokinetics of sorafenib toward preferable parameters.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Radiation; Enzyme Induction; Humans; Liver Neoplasms; Male; NF-kappa B; Portal Vein; Protein Kinase Inhibitors; Radiosurgery; Rats; Rats, Sprague-Dawley; Retrospective Studies; Sorafenib; Specific Pathogen-Free Organisms; Tissue Distribution; Venous Thrombosis | 2020 |
Successful management of the hepatocellular carcinoma with inferior vena cava tumor thrombus: A case report.
Topics: Carcinoma, Hepatocellular; Chemoradiotherapy, Adjuvant; Hepatectomy; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Radiosurgery; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2021 |
Hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein thrombosis: a case-control study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studies; Cisplatin; Doxorubicin; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Portal Vein; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2021 |
Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and Bayesian analysis.
Topics: Bayes Theorem; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Portal Vein; Propensity Score; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis | 2021 |
Anlotinib followed by transarterial chemoembolization and radiofrequency ablation is a safe and effective initial treatment for hepatocellular carcinoma patients with portal vein tumor thrombus: A retrospective case series study.
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Neoplasm Invasiveness; Portal Vein; Postoperative Complications; Quinolines; Retrospective Studies; Sorafenib; Survival Rate; Venous Thrombosis | 2021 |
The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Portal Vein; Progression-Free Survival; Sorafenib; Treatment Outcome; Venous Thrombosis | 2018 |
Percutaneous Irreversible Electroporation for Portal Vein Tumor Thrombus: A Case Report.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Electroporation; Humans; Liver Neoplasms; Male; Middle Aged; Portal Vein; Sorafenib; Ultrasonography; Venous Thrombosis | 2017 |
Might Sorafenib combined with radiotherapy be better option for treating hepatocellular carcinoma with portal vein tumour thrombosis?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Venous Thrombosis | 2018 |
Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Delivery Systems; Ethiodized Oil; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Multivariate Analysis; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Venous Thrombosis | 2019 |
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.
Topics: Aged; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis | 2013 |
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombectomy; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2014 |
Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Propensity Score; Proportional Hazards Models; Radiotherapy; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2014 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis | 2015 |
Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Dermatitis; Diarrhea; Fatigue; Female; Fever; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Venous Thrombosis | 2014 |
Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Comorbidity; Drug Interactions; Drug Monitoring; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Platelet Aggregation Inhibitors; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Tumor Burden; Venous Thrombosis | 2015 |
[Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Topics: Antineoplastic Agents; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Venous Thrombosis | 2014 |
Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Comorbidity; Female; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiography; Republic of Korea; Risk Assessment; Severity of Illness Index; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2015 |
Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Hepatic Veins; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Venous Thrombosis | 2015 |
Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiopharmaceuticals; Sorafenib; Venous Thrombosis; Yttrium Radioisotopes | 2016 |
[Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Embolization, Therapeutic; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Powders; Sorafenib; Venous Thrombosis | 2015 |
Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Propensity Score; Radiotherapy; Retrospective Studies; Sorafenib; Venous Thrombosis | 2016 |
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Proportional Hazards Models; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2016 |
Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chi-Square Distribution; Female; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Niacinamide; Odds Ratio; Phenylurea Compounds; Portal Vein; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Venous Thrombosis | 2016 |
Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Propensity Score; Radiopharmaceuticals; Republic of Korea; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis; Yttrium Radioisotopes | 2016 |
Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Survival Rate; Treatment Outcome; Venous Thrombosis | 2017 |
Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.
Topics: Aged; Angiography, Digital Subtraction; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Phlebography; Portal Vein; Protein Kinase Inhibitors; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis | 2016 |
Oesophageal variceal bleeding in hepatocellular carcinoma with portal vein thrombosis: improved outcome in response to molecular target therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Sorafenib; Venous Thrombosis | 2008 |
[Regression of vena cava tumour thrombus in response to sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Follow-Up Studies; Humans; Kidney; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Renal Veins; Sorafenib; Time Factors; Treatment Outcome; Venae Cavae; Venous Thrombosis | 2008 |
Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Head and Neck Neoplasms; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Sorafenib; Treatment Outcome; Venous Thrombosis | 2011 |
[The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cisplatin; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Pilot Projects; Portal Vein; Pyridines; Sorafenib; Venous Thrombosis | 2010 |
Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis | 2011 |
Downsizing a thrombus of advanced renal cell carcinoma in a presurgical setting with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2012 |
[A case of curative resection for advanced hepatocellular carcinoma with portal vein tumor thrombus after hepatic arterial infusion chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Venous Thrombosis | 2012 |